Highlights Active Biotech AB London S.E.

Equities

0GQU

SE0001137985

Market Closed - London S.E. Other stock markets 09:57:30 2021-02-02 am EST			5-day change	1st Jan Change
1.52 ^SEK	-8.13%		+50.02%	+50.02%

Jul. 01	Active Biotech Enters Agreement for A Clinical Study of Tasquinimod in Myelofibrosis	CI
May. 22	Active Biotech Secures Exclusive Licensing Rights to Multiple Myeloma Drug	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Active Biotech Enters Agreement for A Clinical Study of Tasquinimod in Myelofibrosis	Jul. 01	CI
Active Biotech Secures Exclusive Licensing Rights to Multiple Myeloma Drug	May. 22	MT
Active Biotech Enters into an Exclusive License Agreement with the Wistar Institute of Anatomy and Biology	May. 22	CI
Active Biotech AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops	Apr. 03	CI
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 08	CI
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
Active Biotech AB Provides Update on the Scheduled Clinical Program for 2024	Dec. 22	CI
Active Biotech Teams Up with US Research Group on Clinical Study of Laquinimod Eye Drops	Dec. 06	MT
Rights Issue: 3 new shares @ 0.45 SEK for 7 existing shares	Nov. 14	FA
Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Active Biotech AB Announces Two Abstracts with Preclinical Data for Tasquinimod in Myelofibrosis and Myelodysplastic Syndrome Have Been Accepted for Presentation At Ash 2023	Nov. 02	CI
Active Biotech AB Announces Successful Completion of Dose Escalation of Tasquinimod	23-09-11	CI
Active Biotech AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Active Biotech Signs Collaboration Deal For Blood Cancer Drug Clinical Trial	23-07-31	MT
Active Biotech AB Enters into Clinical Trial Collaboration Agreement for a Clinical Study with Tasquinimod in Myelofibrosis	23-07-31	CI
Active Biotech Announces Positive Interim Data from an Ongoing Study with Tasquinimod in Relapsed and Refractory Multiple Myeloma	23-05-26	CI
Active Biotech AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-09	CI
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Active Biotech AB London S.E.

Equities

0GQU

SE0001137985

Highlights

Filters